This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wright, A. S. Articles by Rittmaster, R. S. Search for Related Content PubMed PubMed Citation Articles by Wright, A. S. Articles by Rittmaster, R. S.

Androgen-Induced Regrowth in the Castrated Rat Ventral Prostate: Role of 5-Reductase¹

Departments of Physiology and Biophysics (A.S.W., R.C.D., L.N.T., R.S.R.), Biochemistry (C.B.L.) and Medicine (R.S.R.), Dalhousie University, Halifax, Nova Scotia, Canada, B3H 4H7

Address all correspondence and requests for reprints to: A. Stuart Wright, Department Physiology and Biophysics, Tupper Building, Dalhousie University, Halifax, Nova Scotia, Canada, B3H 4H7. E-mail: aswright{at}is2.dal.ca

Testosterone (T), the major circulating androgen, must be converted to dihydrotestosterone (DHT) by the enzyme 5-reductase (5-R) to be maximally active in the prostate. The present study was designed to determine the relative potency of T and DHT on regrowth of the involuted prostate and to elucidate the role of 5-R in the growing prostate. To create dose-response curves for intraprostatic T or DHT, rats were castrated for 2 weeks to allow their prostates to fully regress and then given T implants of various sizes in the presence or absence of the 5-R inhibitor, finasteride. Markers for androgen effects on regrowth of the prostate were prostate weight, duct mass (a measure of secretory activity) and DNA content (a measure of cell number). To assess the relative uptake of T and DHT by the prostate, a comparison was made of intraprostatic DHT levels resulting from T and DHT implants.

In the prostate, 1.6–1.9 times more T than DHT was required to achieve a half-maximal response for each of the three markers of prostate regrowth. The dose-response curves revealed that thresholds for intraprostatic T and DHT had to be attained before significant growth was observed. The threshold for T was 2- to 3-fold greater than that for DHT. However, at high intraprostatic concentrations, the effects of T mimicked those of DHT. When the relationship between serum T levels and prostate regrowth was considered, 13 times more serum T was required for half-maximal prostate regrowth when its conversion to DHT was blocked by finasteride. This is partly due to decreased androgen accumulation in the prostate when T was the major intraprostatic androgen. Finally, T or DHT implants in the absence of finasteride resulted in similar intraprostatic DHT levels, indicating that uptake of each serum androgen into the prostate was similar. However, to achieve similar levels of DHT or T in serum, much larger DHT pellets were needed, suggesting more rapid metabolism of DHT in tissues other than the prostate.

We conclude that the role of 5-R is 2-fold: it converts testosterone into a modestly more potent androgen and enhances prostatic accumulation of androgen. DHT, in principle, could serve equally well as T as the circulating androgen, although the rate of DHT production would have to be considerably higher to counter the apparent rapid clearance from serum. In addition, we hypothesize that T has arisen as the major circulating androgen instead of DHT because it can be aromatized to estradiol, which itself has important roles in male reproductive function and bone physiology.

This article has been cited by other articles:

				V. R. Placencio, A.-R. Sharif-Afshar, X. Li, H. Huang, C. Uwamariya, E. G. Neilson, M. M. Shen, R. J. Matusik, S. W. Hayward, and N. A. Bhowmick Stromal Transforming Growth Factor-{beta} Signaling Mediates Prostatic Response to Androgen Ablation by Paracrine Wnt Activity Cancer Res., June 15, 2008; 68(12): 4709 - 4718. [Abstract] [Full Text] [PDF]

				R. B. Montgomery, E. A. Mostaghel, R. Vessella, D. L. Hess, T. F. Kalhorn, C. S. Higano, L. D. True, and P. S. Nelson Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth Cancer Res., June 1, 2008; 68(11): 4447 - 4454. [Abstract] [Full Text] [PDF]

				S. R. Plymate, K. Haugk, I. Coleman, L. Woodke, R. Vessella, P. Nelson, R. B. Montgomery, D. L. Ludwig, and J. D. Wu An Antibody Targeting the Type I Insulin-like Growth Factor Receptor Enhances the Castration-Induced Response in Androgen-Dependent Prostate Cancer Clin. Cancer Res., November 1, 2007; 13(21): 6429 - 6439. [Abstract] [Full Text] [PDF]

				W. Gao and J. T. Dalton Ockham's Razor and Selective Androgen Receptor Modulators (SARMs): Are We Overlooking the Role of 5{alpha}-Reductase? Mol. Interv., February 1, 2007; 7(1): 10 - 13. [Abstract] [Full Text] [PDF]

				L. K. Potter, M. G. Zager, and H. A. Barton Mathematical model for the androgenic regulation of the prostate in intact and castrated adult male rats Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E952 - E964. [Abstract] [Full Text] [PDF]

				A. Armagan, N. N. Kim, I. Goldstein, and A. M. Traish Dose-Response Relationship Between Testosterone and Erectile Function: Evidence for the Existence of a Critical Threshold J Androl, July 1, 2006; 27(4): 517 - 526. [Abstract] [Full Text] [PDF]

				M. Marberger, C. G. Roehrborn, L. S. Marks, T. Wilson, and R. S. Rittmaster Relationship among Serum Testosterone, Sexual Function, and Response to Treatment in Men Receiving Dutasteride for Benign Prostatic Hyperplasia J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1323 - 1328. [Abstract] [Full Text] [PDF]

				W. Gao, J. D. Kearbey, V. A. Nair, K. Chung, A. F. Parlow, D. D. Miller, and J. T. Dalton Comparison of the Pharmacological Effects of a Novel Selective Androgen Receptor Modulator, the 5{alpha}-Reductase Inhibitor Finasteride, and the Antiandrogen Hydroxyflutamide in Intact Rats: New Approach for Benign Prostate Hyperplasia Endocrinology, December 1, 2004; 145(12): 5420 - 5428. [Abstract] [Full Text] [PDF]

				A. Omezzine, C. Mauduit, E. Tabone, N. Nabli, A. Bouslama, and M. Benahmed Caspase-3 and -6 Expression and Activation Are Targeted by Hormone Action in the Rat Ventral Prostate During the Apoptotic Cell Death Process Biol Reprod, September 1, 2003; 69(3): 752 - 760. [Abstract] [Full Text] [PDF]

				W. A. Fritz, I.-E. Eltoum, M. S. Cotroneo, and C. A. Lamartiniere Genistein Alters Growth but Is Not Toxic to the Rat Prostate J. Nutr., October 1, 2002; 132(10): 3007 - 3011. [Abstract] [Full Text] [PDF]

				S. J. McPherson, H. Wang, M. E. Jones, J. Pedersen, T. P. Iismaa, N. Wreford, E. R. Simpson, and G. P. Risbridger Elevated Androgens and Prolactin in Aromatase-Deficient Mice Cause Enlargement, But Not Malignancy, of the Prostate Gland Endocrinology, June 1, 2001; 142(6): 2458 - 2467. [Abstract] [Full Text] [PDF]